Endovenous Ablation With and Without Polidocanol Endovenous Microfoam Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities (017)
This study has been completed.
Sponsor:
BTG Ltd.
Information provided by (Responsible Party):
BTG Ltd.
ClinicalTrials.gov Identifier:
NCT01197833
First received: September 8, 2010
Last updated: March 7, 2013
Last verified: March 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Varicose veins are enlarged, noticeably bulging veins, which commonly occur in the legs and may cause discomfort. In this study, patients with varicose veins in the legs will be participating. The purpose of this research study is to evaluate the safety and effectiveness of two different doses of an investigational drug, Polidocanol Endovenous Microfoam (PEM) compared to vehicle (inactive solution) when used following an approved heat treatment in subjects with varicose veins.
| Condition | Intervention | Phase |
|---|---|---|
|
Great Saphenous Vein Incompetence Visible Varicosities |
Drug: Polidocanol endovenous microfoam (PEM) Drug: vehicle |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Multicenter, Randomized, Blinded Study of Endovenous Thermal Ablation With or Without Varisolve™ Polidocanol Endovenous Microfoam (PEM) Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities |
Resource links provided by NLM:
MedlinePlus related topics:
Varicose Veins
Drug Information available for:
Polidocanol
U.S. FDA Resources
Further study details as provided by BTG Ltd.:
Primary Outcome Measures:
- Absolute change from baseline in appearance of visible varicose veins as assessed by Independent Photography Review (IPR) [ Time Frame: 8 weeks post treatment ] [ Designated as safety issue: No ]
- The absolute change from baseline in the appearance of varicose veins by patient self-assessment [ Time Frame: 8 weeks post-treatment ] [ Designated as safety issue: No ]
| Enrollment: | 105 |
| Study Start Date: | September 2010 |
| Study Completion Date: | December 2012 |
| Primary Completion Date: | March 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: ETA + Low dose polidocanol endovenous microfoam |
Drug: Polidocanol endovenous microfoam (PEM)
Polidocanol endovenous microfoam
|
| Experimental: ETA + Mid dose polidocanol endovenous microfoam |
Drug: Polidocanol endovenous microfoam (PEM)
Polidocanol endovenous microfoam
|
| Placebo Comparator: ETA + vehicle |
Drug: vehicle
All components except API
|
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Incompetence of SFJ
- Patients who are candidates for ETA [laser or radiofrequency ablation (RFA)]
- Symptomatic varicose veins
- Visible varicose veins
- Ability to comprehend and sign an informed consent and complete study questionnaires in English
Exclusion Criteria:
- Patients who only have telangiectatic or reticular veins (Clinical Finding C1, as assessed by CEAP Classification of Venous Disorders)
- Patients who have active ulceration on the leg to be treated (Clinical Finding C6, as assessed by CEAP Classification of Venous Disorders)
- Leg obesity impairing the ability to access the vein to be treated and/or to apply post-procedure compression bandaging and stockings
- Ultrasonographic or other evidence of current or previous deep vein thrombosis or occlusion
- Deep venous reflux unless clinically insignificant in comparison to superficial reflux
- Peripheral arterial disease precluding the wearing of post-procedure compression bandaging and stockings
- Reduced mobility
- History of deep vein thrombosis, pulmonary embolism or stroke, including evidence of prior DVT on duplex ultrasound
- Major surgery, prolonged hospitalization or pregnancy within 3 months of screening
- Major co-existing disease (e.g. malignancy; pulmonary disease; renal or hepatic insufficiency; serious skin disease/condition that may compromise the ability of the patient to comply with the compression protocol, etc.)
- Known allergic response to polidocanol or heparin, including history of heparin-induced thrombocytopenia, and/or multiple allergic reactions
- Current alcohol or drug abuse
- Pregnant or lactating women
- Women of childbearing potential not using effective contraception
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01197833
Locations
| United States, Arizona | |
| Scottsdale, Arizona, United States, 85255 | |
| United States, Florida | |
| Bradenton, Florida, United States, 34209 | |
| United States, Illinois | |
| Oak Brook, Illinois, United States, 60523 | |
| United States, New York | |
| North Tonawanda, New York, United States, 14120 | |
| Stony Brook, New York, United States, 11974 | |
| United States, North Carolina | |
| Charlotte, North Carolina, United States, 28207 | |
| United States, Washington | |
| Kirkland, Washington, United States, 98034 | |
Sponsors and Collaborators
BTG Ltd.
More Information
Additional Information:
Study web site 
No publications provided
| Responsible Party: | BTG Ltd. |
| ClinicalTrials.gov Identifier: | NCT01197833 History of Changes |
| Other Study ID Numbers: | VAP.VV017 |
| Study First Received: | September 8, 2010 |
| Last Updated: | March 7, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by BTG Ltd.:
|
varicose veins Great saphenous vein varicosities |
Additional relevant MeSH terms:
|
Varicose Veins Vascular Diseases Cardiovascular Diseases Polidocanol |
Sclerosing Solutions Cardiovascular Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 22, 2013